Tai'ai (telitacicept) / Rongchang Pharma 
Welcome,         Profile    Billing    Logout  
 0 Diseases   0 Trials   0 Trials   1 News 


«12345»
  • ||||||||||  Tai'ai (telitacicept) / Rongchang Pharma
    Journal:  Effect of Telitacicept on Circulating Gd-IgA1 and IgA-Containing Immune Complexes in IgA Nephropathy. (Pubmed Central) -  May 20, 2024   
    In turn, IgG-IgA or poly-IgA immune complexes showed a dose-dependent effect, consistent with proteinuria reduction during telitacicept treatment. Telitacicept lowered both circulating Gd-IgA1 and IgA-containing immune complexes, whereas IgA immune complex levels were more consistent with decreased proteinuria.
  • ||||||||||  Tai'ai (telitacicept) / Rongchang Pharma
    Retrospective data, Journal, Real-world evidence, Real-world:  Efficacy and safety of telitacicept in patients with lupus nephritis: a single-center, real-world retrospective study. (Pubmed Central) -  Apr 13, 2024   
    Telitacicept treatment reduced disease severity in patients with LN. The initial clinical trial provided supportive evidence for the effectiveness and safety of Telitacicept as a viable treatment option for LN, allowing a reduction in the daily glucocorticoid intake while maintaining a good safety profile, and improving hypocomplementation in LN management.
  • ||||||||||  Benlysta (belimumab) / GSK, Tai'ai (telitacicept) / Rongchang Pharma
    COMPARISON OF TELITACICEPT AND BELIMUMAB IN PATIENTS WITH SLE (Poster View) -  Mar 29, 2024 - Abstract #EULAR2024EULAR_817;    
    Both telitacicept and belimumab performed well regarding SLEDAI. Telitacicept can slightly improve treatment outcomes, especially in addressing serum C4 levels, and as well as IgG levels in patients with lupus nephritis.
  • ||||||||||  Review, Journal:  Advances in the treatment of IgA nephropathy with biological agents. (Pubmed Central) -  Mar 7, 2024   
    There are four main categories of biological agents used to treat IgA nephropathy, specifically anti-CD20 monoclonal antibodies, anti-BLyS or APRIL monoclonal antibodies, monoclonal antibodies targeting both BLyS and APRIL (telitacicept and atacicept), and monoclonal antibodies inhibiting complement system activation (narsoplimab and eculizumab). However, further research on the dosages, treatment duration, long-term efficacy, and safety of these biological agents is required.
  • ||||||||||  Benlysta (belimumab) / GSK, Tai'ai (telitacicept) / Rongchang Pharma, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
    Journal:  The efficacy of rituximab plus belimumab or telitacicept in refractory lupus nephritis. (Pubmed Central) -  Dec 25, 2023   
    N=18 --> 30 Rituximab followed by belimumab or telitacicept may be effective in inducing remission in refractory lupus nephritis, with tolerable adverse effects.
  • ||||||||||  Tai'ai (telitacicept) / Rongchang Pharma
    Trial termination:  A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy (clinicaltrials.gov) -  Dec 6, 2023   
    P2,  N=15, Terminated, 
    Further studies are ongoing to confirm the safety and efficacy of anti-APRIL approaches as an effective therapeutic strategy in IgAN. Active, not recruiting --> Terminated; Decision that continuing with the study would not generate useful data
  • ||||||||||  Tai'ai (telitacicept) / Rongchang Pharma
    Trial completion, Trial completion date, Trial primary completion date:  Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus (clinicaltrials.gov) -  Dec 5, 2023   
    P1,  N=92, Completed, 
    Active, not recruiting --> Terminated; Decision that continuing with the study would not generate useful data Recruiting --> Completed
  • ||||||||||  Benlysta (belimumab) / GSK, Tai'ai (telitacicept) / Rongchang Pharma
    Biomarker, Review, Journal:  Biomarkers Associated with Drugs for the Treatment of Lupus Nephritis. (Pubmed Central) -  Nov 29, 2023   
    If simple, non-invasive and effective biomarkers can be found, drug intervention and prognosis can be better monitored and targeted. In this review, we focus on LN and explore biomarkers related to LN therapeutics, providing clinicians with more possibilities to track the therapeutic effect of drugs, improve treatment options and assess patient outcomes.
  • ||||||||||  Tai'ai (telitacicept) / Rongchang Pharma
    Enrollment open:  Multi-omics Studies on the Efficacy of Telitacicept in Chinese SLE Patients (clinicaltrials.gov) -  Nov 15, 2023   
    P4,  N=30, Recruiting, 
    In this review, we focus on LN and explore biomarkers related to LN therapeutics, providing clinicians with more possibilities to track the therapeutic effect of drugs, improve treatment options and assess patient outcomes. Not yet recruiting --> Recruiting
  • ||||||||||  Review, Journal:  A narrative review of potential drug treatments for nephritis in children with IgA vasculitis (HSP). (Pubmed Central) -  Nov 13, 2023   
    Not yet recruiting --> Recruiting Novel drugs that may be considered for use in early nephritis include TRF-budesonide; B-cell inhibiting agents including belimumab, telitacicept, blisibimod, VIS649, and BION-1301; B-cell depleting agents such as rituximab, ofatumumab, and bortezomib; sparsentan; angiotensin converting enzyme inhibitors (ACE-Is); and complement pathway inhibitors including avacopan, iptacopan, and narsoplimab.
  • ||||||||||  Tai'ai (telitacicept) / Rongchang Pharma
    Journal:  Efficacy and safety of Telitacicept in patients with IgA nephropathy. (Pubmed Central) -  Nov 8, 2023   
    Novel drugs that may be considered for use in early nephritis include TRF-budesonide; B-cell inhibiting agents including belimumab, telitacicept, blisibimod, VIS649, and BION-1301; B-cell depleting agents such as rituximab, ofatumumab, and bortezomib; sparsentan; angiotensin converting enzyme inhibitors (ACE-Is); and complement pathway inhibitors including avacopan, iptacopan, and narsoplimab. No abstract available
  • ||||||||||  Tai'ai (telitacicept) / Rongchang Pharma
    Extracellular potassium increases in unmyelinated and myelinated regions and cortical hyperexcitability (WCC Halls A-C) -  Nov 3, 2023 - Abstract #Neuroscience2023NEUROSCIENCE_5793;    
    Supported By Italian Ministry of Health (RRC), Progetto 5PerMille Ictomyelin RC18...In PC layer I a large and fast increase of extracellular potassium concentration ([K+]o) at the onset of seizure-like event induced by the K+ channel blocker 4-aminopyridine (4AP) was recorded in the guinea pig brain in vitro (Uva 2017 doi: 10...111/epi. 16824), pathological K+ changes could support hyperexcitability.
  • ||||||||||  Tai'ai (telitacicept) / Rongchang Pharma
    Enrollment open:  Study of Telitacicept in Generalized Myasthenia Gravis (clinicaltrials.gov) -  Oct 12, 2023   
    P3,  N=100, Recruiting, 
    ACR20 Response Rate Through Week 24 (NRI, FAS).#P<0.001 vs. Placebo. Not yet recruiting --> Recruiting
  • ||||||||||  Tai'ai (telitacicept) / Rongchang Pharma
    Enrollment open:  A Study of Telitacicept in Lupus Nephritis (clinicaltrials.gov) -  Oct 12, 2023   
    P2,  N=120, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
  • ||||||||||  Tai'ai (telitacicept) / Rongchang Pharma
    Trial completion date, Trial primary completion date:  RC18 in Patients With Relapsing Remitting Multiple Sclerosis?a Phase II Trial (clinicaltrials.gov) -  Oct 11, 2023   
    P2,  N=18, Recruiting, 
    Active, not recruiting --> Completed Trial completion date: Nov 2022 --> Dec 2025 | Trial primary completion date: Apr 2022 --> Oct 2025
  • ||||||||||  Tai'ai (telitacicept) / Rongchang Pharma
    Review, Journal:  Role of telitacicept in the treatment of IgA nephropathy. (Pubmed Central) -  Sep 26, 2023   
    As a dual-target biological agent, telitacicept can inhibit both BLyS and APRIL cytokines, improve the function of renal immune complexes, and reduce haematuria and proteinuria, which play important roles in IgAN pathogenesis and long-term prognosis. This article reviews the role of telitacicept in IgA nephropathy and discusses its potential for use in the treatment of IgAN and other autoimmune diseases where pathogenesis is driven by B cells.
  • ||||||||||  Benlysta (belimumab) / GSK, Tai'ai (telitacicept) / Rongchang Pharma
    WITHDRAWN (Poster Hall; in person) -  Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_4319;    
    Telitacicept showed better efficacy and safety than belimumab for patients with active SLE in multiple clinical centers. Further investigations in larger cohorts and head-to-head clinical trials are required to verify these findings.